AbstractBackgroundAD pathology affects neuronal microstructural decades before clinical manifestation of the disease. Amyloid plaques and tau tangles are key contributors to alterations in brain microstructural properties such as neurite morphology and axonal transport and packing, among others. It takes many years for these microstructural changes to build up and be reliably detected using volumetric MRI measures of neurodegeneration. Here, we examined the utility of neurite imaging – a biologically inspired model for examining cortical microstructure – to examine the impact of amyloid and tau pathology on intra‐ and extra‐cellular properties of cortical tissue and to further improve our mechanistic understanding of AD development.MethodWe utilized multimodal imaging data collected as part of ADNI‐3 including structural, multi‐shell diffusion MRI, and amyloid (18F‐florbetapir) and tau (18F‐flortaucipir) PET. The sample included 90 cognitively normal older adults (CN:23/67 amyloid‐positive/negative, age = 72.0(8.8) years) and 65 older adults with mild cognitive impairment (MCI: 36/29 amyloid‐positive/negative, 73.3(7.2) years). Neurite orientation dispersion and density imaging (NODDI) measures including intracellular volume fraction (ICVF), neurite orientation and dispersion index (ODI) in gray matter, standardized uptake value ratio (SUVR) for amyloid/tau PET and cortical thickness were extracted for 360 regions defined by surface‐based HCP atlas. We performed mediation analyses to examine the interplay between AD pathology and intracellular/extracellular properties of brain tissue and also compared the clinical utility of cortical neurite measures against volumetric MRI in detecting brain changes associated with AD pathology (tau burden) in preclinical AD.ResultMediation analyses showed that tau burden mediates the impact of amyloid on intracellular properties of brain tissue (ICVF) in medial and lateral temporal structures (Fig.1A) whereas ODI is a significant mediator of the effect of extracellular amyloid accumulation on intra‐cellular tau burden in entorhinal cortex (Fig.1B) in amyloid‐positive older adults. Further, among the regions with highest tau burden in amyloid‐positive CN group, ICVF changes in lateral temporal cortex successfully distinguished preclinical AD from amyloid‐negative CN and was associated with tau pathology.ConclusionOverall, these preliminary results suggest that accumulation of amyloid plaques results in reduction of neurite complexity while build‐up of tau reduces the intracellular volume fraction in preclinical stage of AD.